Clinical Trials
36 trialsIV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
SciTech Development, Inc.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
Eastern Cooperative Oncology Group
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
South Plains Oncology Consortium
SPOC2013-001
South Plains Oncology Consortium
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
CerRx, Inc.
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer
M.D. Anderson Cancer Center
Fenretinide in Healthy Young Women at Genetic and Familial Risk
European Institute of Oncology
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
Fenretinide in Treating Patients With Cervical Neoplasia
M.D. Anderson Cancer Center
Fenretinide in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
National Cancer Institute (NCI)
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Fenretinide in Treating Patients With Solid Tumors
Barbara Ann Karmanos Cancer Institute
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
National Cancer Institute (NCI)
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
California Cancer Consortium
Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
GOG Foundation
Combination Chemotherapy in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
National Cancer Institute (NCI)
Fenretinide in Treating Patients With Leukoplakia of the Mouth
University of Alabama at Birmingham
Chemotherapy in Treating Patients With Advanced Kidney Cancer
Barbara Ann Karmanos Cancer Institute
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Fenretinide in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
M.D. Anderson Cancer Center
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
SWOG Cancer Research Network
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
University of Arizona
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
National Institutes of Health Clinical Center (CC)